

RHP Plan Update Provider Form

 $This \ page \ provides \ high-level \ information \ on \ the \ various \ inputs \ that \ a \ user \ will \ find \ within \ this \ template.$

Cell Background Description

Sample Text		Required user input cell, that is necessary for successful completion
	Sample Text	Pre-populated cell that a user CANNOT edit
	Sample Text	Pre-populated cell that a user CAN edit
	Sample Text	Optional user input cell

DY7-8 Provider RHP Plan Update Template - Provider Entry

Progress Indicators

Section 1: Performing Provider Information Section 2: Lead Contact Information

Section 3: Optional Withdrawal From DSRIP Section 4: Performing Provider Overview Section 5: DY7-8 DSRIP Total Valuation

Comple	te
Comple	te

Section 1: Performing Provider Informatio

	RHP:
•	TPI and Performing Provider Name:
	Performing Provider Type:
	Ownership:

Physical Street Address: City:

Primary County:

Additional counties being served (optional):

3
081522701 - Texana Center
ommunity Mental Health Center (CMHC)
on-State Owned Public
7602532875007
010 Airport Avenue
osenberg
7471
ort Bend

ote; you cannot type county inputs; rather, please select your county from the dropdown menu

Section 2: Lead Contact Information

			•
	Lead Contact 1	Lead Contact 2	Lead Contact 3
Contact Name:	Amanda Darr	Shena Timberlake	Brian Gurbach
Street Address:	4910 Airport Avenue, Building D	4910 Airport Avenue, Building B	4910 Airport Avenue, Building B
City:	Rosenberg	Rosenberg	Rosenberg
Zip:	77471	77471	77471
Email:	amanda.darr@texanacenter.com	shena.timberlake@texanacenter.co m	brian.gurbach@texanacenter.com
Phone Number:	281-239-1350	(281) 239-1384	(281) 239-1446
Phone Extension:			
Lead Contact or Both:	Both	Both	Both

Please note that a contact designated "Lead Contact" will be included in the RHP Plan and on the DSRIP Provider Distribution List. A contact designated as

Section 3: Optional Withdrawal From DSRIP

Please select an option below. By selecting "Yes - Withdraw from DSRIP," this organization acknowledges it understands that any DY6 DSRIP payments will be recouped as required by the DY6 Program Funding and Mechanics Protocol. This does not include recoupment of DY4-5 payments that may have occurred in DY6 due to allowable carryforward.

Section 4: Performing Provider Overview

cana Center is a Community Mental Health Center serving six counties. Texana provides services to those with behavioral healthcare (BH) needs Il as those with intellectual and development disabilities (IDD). Texana Center provides outpatient services to those with mental illne habilitative services, case management services along with psychiatric and counseling services in accordance with HHSC's Texas Resilience and very model of service delivery. Texana Center as as the Local Mental Health Authority is the safety net provider for mental health crisis services nd is the gate keeper for admissions to the state hospital system. In addition to behavioral healthcare services, Texana is the Local Intellectual and Performing Provider Description: ental Authority and provides service coordination and completes determination of intellectual and development designation for individual may be entitled to state funded services. Texana operates an IDD provider services division consisting of learning centers and IDD group homes individuals in IDD waiver programs. Texana also operates several specialized programs including the Children's Center for Autism, Behavior ent Center, Social Skills Groups for adults with autism, the Behavior Training and Treatment Center, and Early Childhood Intervention.

ervation unit and crisis residential unit) to serve those in crisis in the least restrictive setting rather than hospitalization. In addition, primary care tegration provides primary care medical services to uninsured individuals in our six county service area. Prior to DSRIP, many of these individuals iffered with untreated and uncontrolled hypertension, diabetes, and other chronic but treatable diseases. These services have further reduced Overall DSRIP Goals: gency room visits for these individuals. These individuals are uninsured and already in our behavioral healthcare services and are now able to

> e 2017 Community Needs Assessment completed by the RHP 3 anchor continues to speak to the needs for behavioral healthcare services and ary care services in our catchment area and our DSRIP goals and core activities continue to address these needs. Texana Center continues to us on crisis services for individuals with behavioral healthcare needs and diverting these individuals from iails and emergency rooms by providing alternative setting to stabilize individuals. In addition, the primary care integration services focuse on acute primary care issues as well as chroni mary care issues primarily uncontrolled hypertension and uncontrolled diabetes. By integrating primary care and behavioral healthcare, we are riking on meeting our region's identified goals. Per Region 3's updated Community Health Needs Assessment, Texana Center is addressing "The ck of primary and specialty care Providers, particularly for uninsured individuals and people requiring behavioral health services, resulting in sufficent access to care and frequent long wait lists for services." In addition, Texana is addressing "Behavioral Health needs continue to grow viding a primary care service provider, we are meeting the needs of over 500 individuals with behavioral health needs and primary care needs tha erwise would not be addressed. With the Crisis Center, we are providing a facility for individuals to stabilize rather than referring to more costly patient psychiatric facilities

Section 5: DY7-8 DSRIP Total Valuation

Alignment with regional community needs

ssessment

•				
		DY7-8 DSRIP Valuation Distribution		
	Valuation if regional private hospit	Valuation if regional private hospital participation requirement is met Valuation if regional private hospital participation		participation requirement is \underline{not} met
	DY7	DY7 DY8		DY8
RHP Plan Update Submission	\$2,266,323.40	\$0.00	\$2,266,323.40	\$0.00
Category A	\$0.00	\$0.00	\$0.00	\$0.00
Category B	\$1,133,161.70	\$1,133,161.70	\$1,133,161.70	\$1,133,161.70
Category C	\$6,232,389.35	\$8,498,712.75	\$7,365,551.05	\$9,631,874.45
Category D	\$1,699,742.55	\$1,699,742.55	\$566,580.85	\$566,580.85
Total	\$11 221 617 00	\$11 221 617 00	\$11 221 617 00	¢11 221 617 00

Would you like to decrease the total valuation?

Have you reviewed and confirmed the valuations listed in the table above and identified available IGT to fund these DSRIP amounts?

[&]quot;Both" will be included in the RHP Plan, on the DSRIP Provider Distribution List, and will be given access to the DSRIP Online Reporting System.

Generate Worksheets

DY7-8 Provider RHP Plan Update Template - Category B

Progress Tracker

Section 1: System Definition

Section 2: Medicaid Low-income Uninsured (MLIU) Patient Population by Provider (PPP)

Complete

Performing Provider Information

KHP:

081522701 - Texana Center

TPI and Performing Provider Name: Performing Provider Type:

Community Mental Health Center (CMHC)

Ownership:

Non-State Owned Public

Category B valuation in DY7: Category B valuation in DY8: \$1,133,161.70 \$1,133,161.70

Section 1: System Definition

Community Mental Health Centers - Required Components

Required System Component Business Component?

Home-based Services

Business Component of the Organization

Please enter a description of this System Component.

Services provided in the six county area served by Texana Center to people with behavioral health issues and intellectual and developmental disabilities. This excludes services where the Center is acting in the role of the Local Intellectual Developmental Disability Authority (LIDDA).

Required System Component Business Component?

Office/Clinic Business Component of the Organization

Please enter a description of this System Component.

Services provided in the six county area served by Texana Center to people with behavioral health issues and intellectual and development disabilities. This excludes services where the Center is acting in the role of the Local Intellectual Developmental Disability Authority (LIDDA). Included in this component are the following clinics: Behavioral Healthcare Clinic at Rosenberg, Behavioral Healthcare Clinic at Sugar Land, Behavioral Healthcare Clinic at Bay City, Behavioral Healthcare Clinic at Wharton, Behavioral

Community Mental Health Centers - Optional Components

Optional System Component	Would you like to select this component?
Hospital	No

Optional System Component Would you like to select this component?

Contracted Clinic No

Optional System Component Would you like to select this component?

School-based Clinic No

Optional System Component Would you like to select this component?

Contracted Inpatient Beds Yes

Please enter a description of this System Component.

Texana Center receives funding from HHSC to purchase beds in local (primarily Houston) psychiatric hospitals for individuals who meet inpatient criteria during a crisis screening. Currently, these hospitals include West Park Springs in Richmond, West Oaks Hospital, Behavioral Hospital of Bellaire, Sun Behavioral Houston, Intracare North, Houston, Behavioral Healthcare Hospital and St. Joseph's Hospital all in Houston

Optional System Component	Would you like to select this component?		
State-funded Community Hospital	No		

Optional System Component Would you like to select this component?

Community Institution for Mental Disease (IMD)

Optional System Component Would you like to select this component?

General Medical Hospital No

Optional System Component Would you like to select this component?

State Mental Health Facility No

Optional System Component Would you like to select this component?
State Mental Retardation Facility No

Optional System Component Would you like to select this component?

Other No

	DY5	DY6
MLIU PPP	6,871	6,765
Total PPP	10,252	10,194

Please indicate the population included in the MLIU PPP

✓Medicaid	✓ Dual Eligible (Medicaid and	 ✓CHIP	□Local Coverage Option (Below	☐Insured on the Exchange
✓ Low-Income (Below	☐Self-Pay	✓Uninsured	Other (please explain below)	

MLIU PPP Goal for each DY (DY7 and DY8):	6,818
Average Total PPP	10,223
MLIU percentage of Total PPP	66.69%

^{*}The MLIU percentage is for informational purposes and will help HHSC determine allowable MLIU PPP variation.

Would you like the MLIU PPP Goal to be	
based on DY5 or DY6 only (as opposed to the	No
average)?	

DY7-8 Provider RHP Plan Update	Template - Category C Selection				
Progress Tracker	· • • • • • • • • • • • • • • • • • • •				
			Note: you must	MPT	23
Section 2: Selection Overview (CMHCs a	nd LHDs only)	Complete	confirm selections	Points Selected	23
Section 3: Selection of Measures for Cor	nmunity Mental Health Centers	Complete	at the bottom of the	Measures Selected	13
Minimum Selection Requirements Met		Yes	page to finish.	Clinical Outcome Selected	Y
MPT Met		Yes		At least 2 measures selected	Y
Performing Provider Information					
RHP:	3		1		
TPI and Performing Provider Name:	081522701 - Texana Center				
Performing Provider Type:	Community Mental Health Center (CMHC)				
Ownership:	Non-State Owned Public				
			•		
If regional private hospital participation		\$6,232,389.35			
requirement is met	Category C valuation in DY8:	\$8,498,712.75			
If regional private hospital participation		\$7,365,551.05			
requirement is <u>not</u> met	Category C valuation in DY8:	\$9,631,874.45			
MINIMUM POINT THRESHOLD (MPT):	2				
		⊒ IPT to maintain their valuation that was confirmed on t	he Provider Entry tah		
Edel i Cilorning i Tovider mast select iv	reasure buildles/measures to meet or exceed their w	in 1 to maintain their valuation that was committed on t	ne i rovider Entry tab		
Section 1: Attributed Population					
Attributed Population for Community M	fined in Category B that meet one of the following c	sitaria during the managerament poriod			
		ne encounter during the year prior to the measurement	woor OP		
	providers system during the measurement year and of	ic encounter during the year prior to the measurement	year On		
ii. Two chedunces with the performing	oroviders system during the measurement year				

Section 2: Selection Overview

Please describe any other attributed population (optional).

Please describe your rationale for the selected measures, and describe the primary system components (clinics, facilities) that will be used to report on and drive improvement in selected measures.

These measures were selected based on the needs of the population that we serve and where we felt we could have the greatest impact in changing the health (behavioral and primary) of those we serve. The measures chosen align with our core activities and with the RHP 3 Community Needs Health Assessment. The Behavioral Healthcare Clinics located in each of the six counties will be the primary source of the denominators used to report on and drive improvement in the selected measures. The primary denominator locations of these clinics are the Behavioral Healthcare Clinic at Rosenberg, Behavioral Healthcare Clinic at Sugar Land, Behavioral Healthcare Clinic at Bay City,

improvement in the selected measures. The primary denominator locations of these clinics are the Behavioral Healthcare Clinic at Rosenberg, Behavioral Healthcare Clinic at Sugar Land, Behavioral Healthcare Clinic at Brookshire. Many of the individuals served in these locations have co-occurring substance abuse disorders, are at high risk for suicide, are at high risk of untreated primary care diseases and the measures chosen drive improvement in these areas for needs that have already been identified by simply serving this population.

Section 3: Selection of Measure Bundles for Community Mental Health Centers

	Additional Points
No M1-103	for State Priority
No single-strates M1-100 Drug Dependence Treatment (IET) Clinical Outcome 3 No M1-103 Controlling High Blood Pressure Clinical Outcome 3 Preventive Care & Screening: Tobacco Use:	Measure
No Mill denominator with significant volume Mi-100 Drug Dependence Treatment (IET) Clinical Outcome 3 Mill denominator with significant volume Mi-103 Control (Ps 0,0%) Control (SAA-PA) Process 1 Mill denominator with significant volume Mi-105 Screening & Cessation Intervention Process 1 Mill denominator with significant volume Mi-105 Mill denominator with significant volume Mi-105 Mill denominator with significant volume Mi-105 Mill denominator with significant volume Mi-126 Mill denominator with significant volume Mi-127 Mill denominator with significant volume Mi-128 Mill denominator with significant volume Mi-129 Mill denominator with signific	
Yes significant volume M1-105 Screening & Cessation Intervention Process 1 No M1-115 (HbA1c) Poor Control (>9.0%) Clinical Outcome 3 No M1-126 M1-125 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-127 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-128 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-129 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-120 M1-125 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-126 Screening for Clinical Depression and Follow-Up Plan (CDF-AD) Process 1 Yes MLU denominator with significant volume M1-160 Follow-Up After Hospitalization for Mental Illness Clinical Outcome 3 No M1-126 Depression Remission at Twelve Months Clinical Outcome 3 No M1-180 Schizophrenia (SAA-AD) Clinical Outcome 3 No M1-180 Schizophrenia (SAA-AD) Clinical Outcome 3 No M1-181 Depression Remission at Twelve Months Clinical Outcome 3 Depression Response at Twelve Months Progress Clinical Outcome 3 Depression Response at Twelve Months Progress Clinical Outcome 3 Depression Response at Twelve Months Progress Clinical Outcome 3 Depression Response at Twelve Months Progress Clinical Outcome 3 Depression Response at Twelve Months Progress Clinical Outcome 3 Depression Response at Twelve Months Progress Clinical Outcome 3 Depression Response at Twelve Months Progress Clinical Outcome 3 Depression Response at Twelve Months Progress Clinical Outcome 3 Depression Response at Twelve Months Progress Clinical Outcome 3 Diabetes Screening for People With Schizophrenia or Biploar Disorder Who Are Using Antipsychotic Process 1 No MLU denominator with Significant volume M1-203 (HCV) for Patients at Risk Process 1 No MLU denominator with Significant volume M1-203 (HCV) for Patients at Risk Process 1 No MLU denominator with Significant volume M1-201 Blood Pressure and Follow-Up Documented Process 1 Will denominator with Significant volume M1-210 Blood Pressure and Follow-Up Documented Process 1 Will denominator wi	1
Yes significant volume M1-105 Screening & Cessation Intervention Process 1 No M1-115 (Initial Duttome M1-105 Screening & Cessation Intervention Process 1 No M1-115 (Initial Duttome M1-105 Screening & Cessation Intervention Process 1 No M1-126 M1-125 Antidepressant Medication Post-Discharge Process 1 No M1-127 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-126 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-127 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-126 Screening for Clinical Depression and Follow-Up Plan (CDF-AD) Process 1 Yes MLU denominator with significant volume M1-147 (BMI) Screening and Follow-Up Plan (Inical Outcome M1-147 (BMI) Screening and Follow-Up Plan (Inical Outcome M1-148 (BMI) Screening and Follow-Up Plan (Inical Outcome M1-149 (BMI) Screening M1-149 (BMI) Screeni	
No Significant volume M1-105 Screening & Cessation Intervention Process 1 No M1-115 Comprehensive Diabetes Care: Hemoglobin A1c (HbAAC) Poor Control (>9.0%) Clinical Outcome 3 No M1-124 Medication Reconciliation Post-Discharge Process 1 No M1-125 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-126 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-127 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-128 Screening for Clinical Depression and Follow-Up Plan (CD-AD) Process 1 Yes MLIU denominator with significant volume M1-147 (BMM) Screening and Follow-Up Plan (DD-AD) Process 1 Yes MILU denominator with significant volume M1-160 Follow-Up After Hospitalization for Mental illness Clinical Outcome 3 No M1-180 Depression Remission at Twelve Months Clinical Outcome 3 Adherence to Antipsychotics for individuals with Schizophrenia (SAA-AD) Clinical Outcome 3 No M1-180 Schizophrenia (SAA-AD) Clinical Outcome 3 Adherence to Antipsychotics for individuals with Schizophrenia (SAA-AD) Clinical Outcome 3 W1-181 Depression Remission at Twelve Months - Progress 1 Towards Remission Clinical Outcome 3 M1-182 Medications (SSD-AD) Process 1 Yes MLU denominator with significant volume M1-182 Medications (SSD-AD) Process 1 No M1-182 Medications (SSD-AD) Process 1 No M1-183 Hepatitis C One-Time Screening for Hepatitis C Virus Medications (SSD-AD) M1-184 Process 1 No M1-185 M-186 M	
Significant volume M1-105 Screening & Cessation Intervention Process 1 No M141 M1-115 (Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Poor Control (>9.0%) Clinical Outcome 3 No M1-124 Medication Reconciliation Post-Discharge Process 1 No M1-125 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-125 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-126 Screening for Clinical Depression and Follow-Up Plan (CD-AD) Process 1 Yes MLIU denominator with significant volume M1-146 (BMI) Screening and Follow-Up After Hospitalization for Mental Illness Clinical Outcome 3 No M1-126 Depression Remission at Twelve Months Clinical Outcome 3 No M1-127 Depression Remission at Twelve Months Clinical Outcome 3 No M1-128 Depression Remission at Twelve Months Clinical Outcome 3 No M1-128 Depression Remission at Twelve Months Clinical Outcome 3 No M1-128 Depression Remission at Twelve Months Clinical Outcome 3 No M1-128 Depression Response at Twelve Months Clinical Outcome 3 No M1-129 Depression Response at Twelve Months Progress Towards Remission Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD-AD) Process 1 No M1-129 MILU denominator with significant volume M1-203 (HCV) for Patients at Risk Process 1 No M1-129 Diabetes Care: BP control (<140/90mm Hg) Clinical Outcome 3 No M1-120 Diabetes Care: BP control (<140/90mm Hg) Clinical Outcome 3 Weight Assessment and Counseling for Nutrition and Process 1 Weight Assessment and Counseling for Nutrition and Process 1 Weight Assessment and Counseling for Nutrition and Process 1 Weight Assessment and Counseling for Nutrition and Process 1 Weight Assessment and Counseling for Nutrition and Process 1 Weight Assessment and Counseling for Nutrition and Process 1 Weight Assessment and Counseling for Nutrition and Process 1 Risk Adjusted Behavioral Healthy Substance Abuse	ł
No M1-115 (HbA1c) Poor Control (>9.0%) Clinical Outcome 3 No M1-124 Medication Reconciliation Post-Discharge Process 1 No M1-125 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-126 Screening for Clinical Depression and Follow-Up Plan (CDF-AD) Process 1 Yes MLIU denominator with significant volume M1-147 (8MI) Screening and Follow-Up Process 1 Yes MILU denominator with significant volume M1-160 Follow-Up After Hospitalization for Mental Illness Clinical Outcome 3 No M1-125 M1-126 Depression Remission at Twelve Months Clinical Outcome 3 No M1-126 Depression Remission at Twelve Months Clinical Outcome 3 No M1-126 Depression Remission at Twelve Months Clinical Outcome 3 No M1-127 Depression Response at Twelve Months Clinical Outcome 3 No M1-127 Depression Response at Twelve Months Progress Towards Remission M1-181 Depression Response at Twelve Months Process 1 Yes MLIU denominator with significant volume M1-182 Hepatitis C. One-Time Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD-AD) Process 1 No M1-120 Hepatitis C. One-Time Screening for Hepatitis C Virus Process 1 No M1-205 Third next available appointment Process 1 No M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 Weight Assessment and Counseling for Nutrition and Process 1 Weight Assessment and Counseling for Nutrition and Process 1 Weight Assessment and Counseling for Nutrition and Process 1 Weight Assessment and Counseling for Nutrition and Process 1 No MLIU denominator with significant volume M1-210 Risk Adjusted Behavioral Healthy Substance Abuse	
No	ł
No M1-125 Medication Reconciliation Post-Discharge Process 1 No M1-125 Antidepressant Medication Management (AMM-AD) (Inical Outcome 3 No M1-125 Screening for Clinical Depression and Follow-Up Plan (CDF-AD) Process 1 Ves MLIU denominator with significant volume M1-147 (8MI) Screening and Follow-Up Process 1 Ves MLIU denominator with significant volume M1-165 Depression Remission at Twelve Months Clinical Outcome 3 No M1-180 Schizophrenia (SAM-AD) Clinical Outcome 3 No M1-181 Towards Remission at Twelve Months Clinical Outcome 3 No M1-181 Towards Remission at Twelve Months Clinical Outcome 3 M1-181 Towards Remission at Twelve Months Progress Clinical Outcome 3 M1-181 Towards Remission at Twelve Months Progress Clinical Outcome 3 M1-181 Towards Remission at Twelve Months-Progress Clinical Outcome 3 M1-181 Towards Remission at Twelve Months-Progress Clinical Outcome 3 M1-181 Towards Remission Outcome 3 M1-181 Towards Remission Outcome 3 M1-181 Towards Remission Clinical Outcome 3 M1-181 Towards Remission Clinical Outcome 3 M1-182 Medication (SSD-AD) Process 1 M1-183 M1-184 Medication (SSD-AD) Process 1 M1-184 M1-185 M1-18	
No M1-125 Medication Reconciliation Reconciliation Reconciliation Post-Discharge Process 1 No M1-125 Antidepressant Medication Management (AMM-AD) Clinical Outcome 3 No M1-146 (CDF-AD) Process 1 Yes MLIU denominator with significant volume M1-147 (BMI) Screening and Follow-Up Plan Process 1 Yes MLIU denominator with significant volume M1-160 Follow-Up After Hospitalization for Mental Illness Clinical Outcome 3 No M1-146 (Pollow-Up After Hospitalization for Mental Illness Clinical Outcome 3 No M1-146 Depression at Twelve Months Clinical Outcome 3 No M1-147 (BMI) Screening and Follow-Up Process 1 Yes MLIU denominator with significant volume M1-160 Depression Remission at Twelve Months Clinical Outcome 3 No M1-147 (BMI) Screening For Process 1 M1-148 Depression Remission at Twelve Months Clinical Outcome 3 Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD) Clinical Outcome 3 M1-181 Towards Remission at Twelve Months- Progress Depression Response at Twelve Months- Progress Depression Response at Twelve Months- Progress Diabetes Screening for People With Schizophrenia or Bipolar Screening for People With Schizophrenia or Bipolar Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD-AD) Process 1 No M1-182 Medications (SSD-AD) Process 1 No M1-183 M1-205 Third next available appointment Process 1 No M1-205 Third next available appointment Process 1 Yes MLIU denominator with significant volume M1-210 Blood Pressure and Follow-Up Documented Process 1 Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents Process 1 Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents Process 1	ł
No MILU denominator with significant volume M1-165 Depression Remission at Twelve Months For Dialocal Outcome M1-181 Dialocal Screening for Property Milu denominator with significant volume M1-165 Depression Remission at Twelve Months Glinical Outcome M1-180 Clinical Outcome M1-180 Clinical Outcome M1-180 Depression Remission at Twelve Months Glinical Outcome M1-180 Depression Remission Remission At Twelve Months Glinical Outcome M1-180 Depression Response at Twelve Months-Progress Towards Remission Clinical Outcome M1-181 Depression Response at Twelve Months-Progress Depression Response at Twelve Months-Progress Depression Response at Twelve Months-Progress M1-181 Depression Response at Twelve Months-Progress Depression Response at Twelve Months-Progress M1-181 Depression Response at Twelve Months-Progress Depression Response at Twelve Months-Progress M1-181 Depression Remission At Twelve M1-181 Depression Remission At Twelve M1-181 Depression Remi	
No	
No MILU denominator with significant volume M1-146 (CDF-AD) Process 1	
MI-146 (CD-AD) MI-146 (CD-AD) Process 1 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Process 1 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Process 1 MI-147 (BMI) Screening and Follow-Up Process 1 No MI-150 Depression Remission at Twelve Months Clinical Outcome 3 Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD) Clinical Outcome 3 Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD) Clinical Outcome 3 No MI-180 Depression Remission Twelve Months Progress Towards Remission Towards Remission Clinical Outcome 3 Depression Response at Twelve Months- Progress Clinical Outcome 3 Depression Response at Twelve Months- Progress Clinical Outcome 3 Diabetes Screening for People With Schizophrenia or Biploar Disorder Who Are Using Antipsychotic Medications (SSD-AD) Process 1 Process 1 Process 1 No MI-181 Hepatitis C: One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk Process 1 No MI-203 (HCV) for Patients at Risk Process 1 No MI-205 Third next available appointment Process 1 Process 1 Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented Process 1 Weight Assessment and Counselling for Nutrition and Significant volume MI-211 Weight Assessment and Counselling for Nutrition and Physical Activity for Children / Adolescents Process 1 Risk Adjusted Behavioral Healthy Substance Abuse	
Yes significant volume M1-147 (BMI) Screening and Follow-Up Process 1 Yes MLU denominator with significant volume M1-160 Follow-Up After Hospitalization for Mental Illness Clinical Outcome 3 No M1-165 Depression Remission at Twelve Months Clinical Outcome 3 Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD) Clinical Outcome 3 No M1-180 Schizophrenia (SAA-AD) Clinical Outcome 3 No M1-181 Depression Remission at Twelve Months Progress Clinical Outcome 3 Depression Response at Twelve Months- Progress Clinical Outcome 3 Depression Response at Twelve Months- Progress Clinical Outcome 3 Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD-AD) Process 1 Yes MLIU denominator with significant volume M1-182 Medications (SSD-AD) Process 1 No M1-182 M-183 M-184 M-185	-
Yes MLIU denominator with significant volume M1-147 (BMI) Screening and Follow-Up Process 1	
No M1-165 Depression Remission at Twelve Months Clinical Outcome 3 No M1-165 Depression Remission at Twelve Months Clinical Outcome 3 No M1-180 Schizophrenia (Subjective to Antipsychotics for Individuals with Schizophrenia or Burland (Subjective to Antipsychotic Subjective to Antipsychotic Subjective to Antipsychotic Subjective to Antipsychotic M1-181 Towards Remission Clinical Outcome 3 Diabetes Creening for People With Schizophrenia or Biploal Process 1 MLIU denominator with significant volume M1-182 Medications (SSD-AD) Process 1 MLIU denominator with Significant volume M1-203 M1-203 Third next available appointment Process 1 No M1-205 Third next available appointment Process 1 No M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 M1-210 Blood Pressure and Follow-Up Documented Process 1 Weight Assessment and Counseling for Nutrition and Process 1 Weight Assessment and Counseling for Nutrition and Process 1 Risk Adjusted Behavioral Healthy Substance Abuse	-
No	
No M1-165 Depression Remission at Twelve Months Clinical Outcome 3 Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD) Clinical Outcome 3 No M1-180 Schizophrenia (SAA-AD) Clinical Outcome 3 Depression Response at Twelve Months- Progress Clinical Outcome 3 Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD-AD) Process 1 Yes MLIU denominator with significant volume M1-182 Hepatitis C: One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk Process 1 No M1-205 Third next available appointment Process 1 No M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 Yes MLIU denominator with Significant volume M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 Weight Assessment and Counselling for Nutrition and Significant volume M1-211 Physical Activity for Children/ Adolescents Process 1 Risk Adjusted Behavioral Healthy Substance Abuse	
No M1-180 Adherence to Antipsychotics for Individuals with Schizophrenia (Schizophrenia (Schizophrenia Ostrophrenia Ostrop	
No Shift state with Significant volume M1-180 Schizophrenia (SAA-AD) Clinical Outcome 3 No MILU denominator with significant volume M1-182 Medication (SSD-AD) Process 1 Yes MLIU denominator with significant volume M1-203 (HCV) for Patients at Risk Process 1 No M1-205 Third next available appointment Process 1 No M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 MILU denominator with significant volume M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 MILU denominator with significant volume M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 MILU denominator with significant volume M1-210 Blood Pressure and Screening: Screening for High Blood Pressure and Follow-Up Documented Process 1 MILU denominator with significant volume M1-210 Process 1 MILU denominator with significant volume M1-210 Risk Adjusted Behavioral Healthy Substance Abuse Nace Additional Process 1 MILU denominator with Significant volume M1-211 Process 1 Weight Assessment and Counseling for Nutrition and Significant volume Physical Activity for Children/ Adolescents Process 1	l
No MI-181 Depression Response at Twelve Months- Progress Towards Remission Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD-AD) Yes MLIU denominator with significant volume M1-182 Medications (SSD-AD) Hepatitis C One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk No M1-203 (HCV) for Patients at Risk No M1-205 Third next available appointment Process 1 No M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 Yes MLIU denominator with significant volume M1-210 Blood Pressure and Follow-Up Documented Process 1 Weight Assessment and Counseling for Nutrition and significant volume M1-211 Physical Activity for Poliderol, Adolescents Process 1 Risk Adjusted Behavioral Healthy Substance Abuse	ł
MILU denominator with significant volume M1-203 MILU denominator with significant volume M1-205 MILU denominator with significant volume M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome M1-210	l
MEDIC denominator with significant volume M1-182 Medications (SSD-AD) Process 1	
Yes MLIU denominator with significant volume M1-203 (HCV) for Patients at Risk Process 1 No M1-205 Third next available appointment Process 1 No M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 Yes MLIU denominator with significant volume M1-201 W1-201 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 Yes MLIU denominator with significant volume M1-210 Blood Pressure and Follow-Up Documented Process 1 Yes MLIU denominator with significant volume M1-210 Weight Assessment and Counseling ror Nutrition and significant volume M1-211 Physical Activity for Children/ Adolescents Process 1 Risk Adjusted Behavioral Healthy Substance Abuse	
Significant volume M1-182 Medications (SSD-AD) Process 1	
Yes	ł
No MI-203 (HCV) for Patients at Risk Process 1	
No M1-205 Third next available appointment Process 1 No M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 Yes MLIU denominator with significant volume M1-210 Blood Pressure and Screening: Screening for High Blood Pressure and Follow-Up Documented Process 1 Yes MLIU denominator with significant volume M1-210 Weight Assessment and Counseling for Nutrition and Spinificant volume M1-211 Physical Activity for Children/ Adolescents Process 1 Risk Adjusted Behavioral Health/ Substance Abuse	ł
M1-205 Third next available appointment Process 1 No M1-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 Yes MLIU denominator with significant volume M1-210 Blood Pressure and Follow-Up Documented Process 1 Yes MLIU denominator with significant volume M1-210 Weight Assessment and Counseling for Nutrition and Significant volume M1-211 Physical Activity for Children/ Adolescents Process 1 Risk Adjusted Behavioral Health/ Substance Abuse	
No MI-207 Diabetes care: BP control (<140/90mm Hg) Clinical Outcome 3 Yes MLIU denominator with significant volume M1-210 Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented Process 1 Yes MLIU denominator with significant volume M1-211 Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents Process 1 No. 34.0 denominator with	
M1-207 Diabetes care: BP control (c140/90mm Hg) Clinical Outcome 3 Yes MLIU denominator with significant volume M1-210 Blood Pressure and Follow-Up Documented Process 1 Yes MLIU denominator with significant volume M1-211 Weight Assessment and Counseling for Nutrition and process 1 No. 3/410/denominator with Significant volume M1-211 Physical Activity for Children/ Adolescents 1 Risk Adjusted Behavioral Health/ Substance Abuse	
MLIU denominator with significant volume M1-210 M1-2	
Yes significant volume M1-210 Blood Pressure and Screening: Screening for High Process 1 Yes MLIU denominator with significant volume M1-211 Weight Assessment and Counseling for Nutrition and Significant volume M1-211 Physical Activity for Children/ Adolescents Process 1 Risk Adjusted Behavioral Health/ Substance Abuse	
Yes MLIU denominator with significant volume M1-210 Blood Pressure and Follow-Up Documented Process 1 Weight Assessment and Counseling for Nutrition and Significant volume M1-211 Physical Activity for Children/ Adolescents Process 1 Risk Adjusted Behavioral Health/ Substance Abuse	ł
Yes MLIU denominator with significant volume M1-211 Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents Process 1 Risk Adjusted Behavioral Health/ Substance Abuse	
Yes significant volume significant volume M1-211 Physical Activity for Children/ Adolescents Process 1 Risk Adjusted Behavioral Health/ Substance Abuse	
Significant volume M1-211 Physical Activity for Children/ Adolescents Process 1 Risk Adjusted Behavioral Health/ Substance Abuse	
Risk Adjusted Behavioral Health/ Substance Abuse	
Management of the control of the con	
Decrease in mental health admissions and	
No readmissions to criminal justice settings such as jails	
M1-241 or prisons Culminal justice settings such as jails Clinical Outcome 3	
wi-z41 or prisons follow-up Care for Children Prescribed ADHD	
No M1-255 Medication (ADD) Clinical Outcome 3	

No						
		M1-256	Initiation of Depression Treatment	Process	1	0
W	MLIU denominator with					
Yes	significant volume	M1-257	Care Planning for Dual Diagnosis	Process	1	0
			Assignment of Primary Care Physician to Individuals			
No		M1-259	with Schizophrenia	Process	1	0
		WI 255	With Schizophi Chia	110003		
No		M1-260	A Dhusian Funn for Donor with Mantal III	D	4	4
		IVI1-260	Annual Physical Exam for Persons with Mental Illness	Process		1
No			Assessment for Substance Abuse Problems of	_		
		M1-261	Psychiatric Patients	Process	1	1
No						
		M1-262	Assessment of Risk to Self/ Others	Process	1	0
No			Assessment for Psychosocial Issues of Psychiatric			
140		M1-263	Patients	Process	1	0
	MLIU denominator with					
Yes	significant volume	M1-264	Vocational Rehabilitation for Schizophrenia	Process	1	0
			Housing Assessment for Individuals with			
No		M1-265	Schizophrenia	Process	1	1
					*	
No			Independent Living Skills Assessment for Individuals			
		M1-266	with Schizophrenia	Process	1	0
			The second of th			· ·
No		M1-280	Chlamydia Screening in Women (CHL)	Process	1	1
		IVI 1-700	Chiamydia Screening III Women (CRL)	FTOCESS	1	1
No		NAA 200	December Description of City Manager	Clinian LOutern		
		M1-286	Depression Remission at Six Months	Clinical Outcome	3	1
No			Documentation of Current Medications in the	_		
		M1-287	Medical Record	Process	1	1
	MLIU denominator with					
Yes	significant volume		Child and Adolescent Major Depressive Disorder			
	significant volume	M1-305	(MDD): Suicide Risk Assessment (SRA-CH)	Process	1	1
No			Use of First-Line Psychosocial Care for Children and			
140		M1-306	Adolescents on Antipsychotics (APP-CH)*	Process	1	0
Yes	MLIU denominator with		Preventive Care and Screening: Unhealthy Alcohol			
Yes	significant volume	M1-317	Use: Screening & Brief Counseling	Process	1	1
	MLIU denominator with		Adult Major Depressive Disorder (MDD): Suicide Risk			
Yes	significant volume	M1-319	Assessment (eMeasure)	Process	1	1
	ŭ.		Alcohol & Other Drug Use Disorder Treatment			
			Provided or Offered at Discharge SUB-3 / Alcohol			
No			and Other Drug Use Disorder Treatment at			
		M1-339	Discharge SUB-3a	Process	1	1
		WIT 333	Substance use disorders: Percentage of patients	1100033	-	
No			aged 18 years and older with a diagnosis of current			
140		M1-340	opioid addiction who were counseled regarding	Process	1	1
		IVIT 340	opiola addiction who were counseled regarding	1100033	1	1
			Substance use disorders: Percentage of patients			
			aged 18 years and older with a diagnosis of current			
No.			alcohol dependence who were counseled regarding			
No						
			psychosocial AND pharmacologic treatment options			
			for alcohol dependence within the 12 month			
M1		M1-341	reporting period	Process	1	1
No	No		Time to Initial Evaluation: Evaluation within 10			
		M1-342 Business Days		Process	1	0
No		Assessment of Functional Status or QoL (Mod				
.40	M1-385		from NQF# 0260/2624)	Quality of Life	1	0
No	No		Improvement in Functional Status or QoL (Modified			
No M1-386		M1-386	from PQRS #435)	Quality of Life	1	0
No		Reduce Emergency Department visits for Behavioral				
NO M1-387		Health and Substance Abuse (Reported as two rates)	Clinical Outcome	3	1	
			(cop a cop		,	
No		M1-390	Time to Initial Evaluation: Mean Days to Evaluation	Process	1	0
	MLIU denominator with	330	Tobacco Use and Help with Quitting Among		-	U
Yes	significant volume	M1-400	Adolescents	Process	4	4
	significant volume	IVI 1-4UU		Process	1	1
No		M1-405	Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use	Process		
NO						

Total overall selected points: 23

Are you finished making your selections?

DY7-8 Provider RHP Plan Update Template - Category C Additional Details

Progress Tracker

Section 1: Measure Exemption Requests and Measure Setting System Components

Complete

Section 1: Measure Exemption Requests and Measure Setting System Components

In order to be eligible for payment for a measure's reporting milestone, the Performing Provider must report its performance on the all-payer, Medicaid-only, and LIU-only payer types. Performing Providers may request to be exempted from reporting a measure's performance on the Medicaid-only payer type or the LIU-only payer type with good cause, such as data limitations. Note that reporting a measure's all-payer performance is still required to be eligible for payment for a measure's reporting milestone.

milestone.							
Pundlo Mossur- 15	Measure Name			Baseline Measurement Period	Requesting a shorter or delayed measurement period?	Beginsting a consting wiletons over-11-3	Requesting a baseline numerator of zero?
Bundle-Measure ID M1-105		Screening: Tobacco Use: S tion	creening &	CY2017: January 1, 2017 - December 31, 2017	Requesting a shorter and delayed baseline measurement period	Requesting a reporting milestone exemption? No	No
Requested Baseline Measurement Period Start Date	10/1/2017	Requested Baseline Measurement Period End Date	9/30/2018	Please enter an explanation for this request	Processes were not implemented to collect th	is data until the second half of the calendar year.	
M1-147	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up		CY2017: January 1, 2017 - December 31, 2017	Requesting a shorter baseline measurement period	No	No	
Requested Baseline Measurement Period Start Date	7/1/2017	Requested Baseline Measurement Period End Date	12/31/2017	Please enter an explanation for this request	Processes were not implemented to collect th approximate baseline.	is data until the second half of the calendar year. Provider is requesting the u	se of an
M1-160	Follow-Up After Ho	spitalization for Mental II	Iness	CY2017: January 1, 2017 - December 31, 2017	No	No	No
M1-182		for People With Schizopl Jsing Antipsychotic Media		CY2017: January 1, 2017 - December 31, 2017	Requesting a shorter baseline measurement period	No	No
Requested Baseline Measurement Period Start Date	7/1/2017	Requested Baseline Measurement Period End Date	12/31/2017	Please enter an explanation for this request	Processes were not implemented to collect th	is data until the second half of the calendar year.	•
M1-203	Hepatitis C: One-Ti Patients at Risk	me Screening for Hepatiti	s C Virus (HCV) for		Requesting a shorter baseline measurement period	No	No
Requested Baseline Measurement Period Start	7/1/2017	Requested Baseline Measurement Period	12/31/2017	Please enter an explanation for this	Processes were not implemented to collect th	is data until the second half of the calendar year.	
Date M1-210	Preventive Care and Pressure and Follov	End Date d Screening: Screening fo v-Up Documented	r High Blood	request CY2017: January 1, 2017 - December 31, 2017	Requesting a shorter baseline measurement period	No	No
Requested Baseline Measurement Period Start Date	7/1/2017	Requested Baseline Measurement Period End Date	12/31/2017	Please enter an explanation for this request	Processes were not implemented to collect th	is data until the second half of the calendar year.	
M1-211	Weight Assessment Activity for Children	and Counseling for Nutr	ition and Physical	CY2017: January 1, 2017 - December 31, 2017	Requesting a shorter baseline measurement period	No	No
Requested Baseline Measurement Period Start Date	7/1/2017	Requested Baseline Measurement Period End Date	12/31/2017	Please enter an explanation for this request	Processes were not implemented to collect this data until the second half of the calendar year. Provider is requesting t approximate baseline.		
M1-257	Care Planning for D	ual Diagnosis		CY2017: January 1, 2017 - December 31, 2017	Requesting a shorter baseline measurement period	No	No
Requested Baseline Measurement Period Start Date	7/1/2017	Requested Baseline Measurement Period End Date	12/31/2017	Please enter an explanation for this request	Processes were not implemented to collect th	is data until the second half of the calendar year.	
M1-264	Vocational Rehabili	tation for Schizophrenia		CY2017: January 1, 2017 - December 31, 2017	Requesting a shorter baseline measurement period	No	No
Requested Baseline Measurement Period Start Date	7/1/2017	Requested Baseline Measurement Period End Date	12/31/2017	Please enter an explanation for this request	Processes were not implemented to collect th	is data until the second half of the calendar year.	
M1-305	Child and Adolesce Suicide Risk Assessi	nt Major Depressive Diso ment (SRA-CH)	rder (MDD):	CY2017: January 1, 2017 - December 31, 2017	Requesting a shorter baseline measurement period	No	No
Requested Baseline Measurement Period Start Date	7/1/2017	Requested Baseline Measurement Period End Date	12/31/2017	Please enter an explanation for this request	Processes were not implemented to collect th	is data until the second half of the calendar year.	Voodungaannamin
M1-317	Preventive Care and Screening & Brief C	d Screening: Unhealthy A ounseling	cohol Use:	CY2017: January 1, 2017 - December 31, 2017	Requesting a shorter and delayed baseline measurement period	No	No
Requested Baseline Measurement Period Start Date	End Date		Please enter an explanation for this request	Processes were not implemented to collect this data until the second half of the calendar year.			
M1-319	Adult Major Depres Assessment (eMea		ide Risk	CY2017: January 1, 2017 - December 31, 2017	Requesting a shorter baseline measurement period	No	No
Requested Baseline Measurement Period Start Date	7/1/2017	Requested Baseline Measurement Period End Date	12/31/2017	Please enter an explanation for this request	Processes were not implemented to collect th	is data until the second half of the calendar year.	
M1-400	Tobacco Use and H	elp with Quitting Among	Adolescents	CY2017: January 1, 2017 - December 31, 2017	Requesting a shorter and delayed baseline measurement period	No	No
Requested Baseline Measurement Period Start Date				Please enter an explanation for this request	Processes were not implemented to collect th	is data until the second half of the calendar year.	

Progress Tracker

Section 1: Measure Bundle/Measure Valuation

Performing Provider Information

I formation of the second of t	lool.vii.ma	66 222 26
Ownership:	Non-State Owned Public	
Performing Provider Type:	Community Mental Health Center (CMHC)	
TPI and Performing Provider Name:	081522701 - Texana Center	
RHP:	3	

If regional hospital participation requirement is met If regional hospital participation requirement is <u>not</u> met

Valuation for Selected Measures - Community Mental Health Centers

								If regional private hospital participation requirement is not met		
Min			Minimum	Maximum	If regional private hospital pa	rticipation requirement is met	If regional private hospital partic	ipation requirement is <u>not</u> met		
Bundle-			Desired Valuation		Valuation % of					
Measure ID	Denominator Volume	Points	e/	Total	Total	Category C Valuation in DY7	Category C Valuation in DY8	Category C Valuation in DY7	Category C Valuation in DY8	
ivieasure in		Points	76	TOTAL	IOLAI	Category C Valuation III D17	Category C Valuation III D18	Category C Valuation in D17	Category C valuation in D18	
M1-105	MLIU denominator with significant volume	2	7.20%	5.76%	7.70%	\$448,732.03	\$611,907.32	\$530,319.68	\$693,494.96	
M1-147	MLIU denominator with significant volume	1	7.70%	5.76%	7.70%	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33	
M1-160	MLIU denominator with significant volume	3	9.62%	5.76%	9.62%	\$599,555.86	\$817,576.17	\$708,566.01	\$926,586.32	
M1-182	MLIU denominator with significant volume	2	7.70%	5.76%	7.70%	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33	
M1-203	MLIU denominator with significant volume	2	7.20%	5.76%	7.70%	\$448,732.03	\$611,907.32	\$530,319.68	\$693,494.96	
M1-210	MLIU denominator with significant volume	1	7.70%	5.76%	7.70%	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33	
M1-211	MLIU denominator with significant volume	2	7.70%	5.76%	7.70%	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33	
M1-257	MLIU denominator with significant volume	1	7.70%	5.76%	7.70%	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33	
M1-264	MLIU denominator with significant volume	1	7.70%	5.76%	7.70%	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33	
M1-305	MLIU denominator with significant volume	2	7.70%	5.76%	7.70%	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33	
M1-317	MLIU denominator with significant volume	2	7.20%	5.76%	7.70%	\$448,732.03	\$611,907.32	\$530,319.68	\$693,494.96	
M1-319	MLIU denominator with significant volume	2	7.70%	5.76%	7.70%	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33	
M1-400	MLIU denominator with significant volume	2	7.18%	5.76%	7.70%	\$447,485.56	\$610,207.58	\$528,846.56	\$691,568.61	
Total	N/A	23	100.00%	N/A	N/A	\$6,232,389.35	\$8,498,712.75	\$7,365,551.05	\$9,631,874.45	
	Difference between selected	percent and 100%:	0.00%		•					

Your valuation allocations add to 100%.

Are you finished allocating your Category C valuations across your selected measures?

Explanation of Valuation Percent Changes

Overall justification for change in Category C valuation distribution.

Valuation was reduced for measures requiring delayed baselines for cash flow reasons.

Please address the amount of improvement required for the Measure Bundle(s) with increased valuation including estimated baseline and goals for key measures that may require high amounts of improvement within the bundle.

Provider has processes implemented to track? I'day affectare with non-lecender professionals per our performance contract with HHSC. Thi measure requires changing the provider type and adding a 30 day follow up measure. Provider has made these modifications and does not expect difficulty showing improvement in this measure. In addition, this is an outcome measure which has considerable greater impact in

Please address the level of effort required for improvement for the Measure Bundle(s) with increased valuation. The process is already in place and required additional cost for licensed staff to complete measure to specification

Please describe the size of the population impacted as compared to the size of other selected Measure Bundle(s) for the Measure Bundle(s)

DY7-8 Provider RHP Plan Update Template - Category A Core Activities

Progress Tracker

Section 1: Transition from DY2-6 Projects to DY7-8 Provider-Level Outcomes and Core Activities

Section 2: Core Activities

All Selected Measure Bundles/Measures Associated with at Least One Core Activity

Complete
Complete
Complete

Performing Provider Information

RHP:

TPI and Performing Provider Name: Performing Provider Type: Ownership: 3

081522701 - Texana Center

Community Mental Health Center (CMHC)

Non-State Owned Public

Section 1: Transition from DY2-6 Projects to DY7-8 Provider-Level Outcomes and Core Activities

DY6 Project ID	Project Option	Project Summary	Completed/ Continuing	Enter a description for continuation (optional)
RHP 3_081522701.1.1	1.12.2	Enhance service availability of appropriate levels of behavioral health care (applied behavior analysis, ABA, and speech-language pathology for children diagnosed with autism spectrum disorders, ASD) to expand the number of community based settings where behavioral health services may be delivered in underserved areas.		
RHP 3_081522701.1.2	1.13.1	Develop an 8 bed 48-hour extended observation unit and a 14 bed crisis residential unit where individuals in crisis may go to be assessed and stabilized by providing crisis intervention services.	Continuing as Core Activity in DY7-8	
RHP 3_081522701.1.3	1.9.2	Implement a system of early identification and delivery of therapeutic services for children with developmental delays that blends the best aspect of private therapy and a natural environment based model and includes social work and/or monitoring by a child development specialist to support parental involvement and supplement the number of clinical hours recommended.	Completed in DY2	
RHP 3_081522701.2.1	2.13.1	Create a crisis behavioral health care team to intervene to keep individuals in crisis out of the State Support Living Centers, emergency rooms, state mental health hospitals or jail. Individuals dually diagnosed (intellectual and developmental disability, pervasive developmental disorder or mental retardation who have a co-occurring serious and persistent mental illness.	Completed in DY2	
RHP 3_081522701.2.100	2.15.1	This project will hire a primary care physician and other appropriate staff to provide primary care services to the Medicaid and uninsured population currently being served by Texana Center for their mental illness. By providing both services in the same building, by the same performing provider, a "warm" hand off can be made the same day as the visit to the behavioral healthcare provider. The interventions will include screenings, treatment, medication services, education services including disease management and nutrition, exercise and wellness.	Continuing as Core Activity in DY7-8	

Section 2: Core Activities

Please enter your organization's number of Core Activities:

1) Please select the grouping for this Core Activity.

Behavioral Health Crisis Stabilization Services

a) Please select the name of this Core Activity.

Implementation of community-based crisis stabilization alternatives that meet the behavioral health needs of the patients.

b) Please enter a description of this Core Activity

This core activity is the continuation of the Crisis Center. The Crisis Center is an 8 bed extended observation unit and a 14 bed crisis residential unit where individuals experiencing a mental health crisis or on the verge a mental health crisis go in lieu of an admission in a psychiatric hospital. This activity involves over 50 providers (telemedicine psychiatrists, "warm body" psychiatrists, LPHA's and QMHP's). In addition to these providers, the Crisis Center is staffed with RN's, LVN's and rounded by a primary care Nurse Practitioner.

i) Please describe the first Secondary Driver for the above Core Activity (required).

Through crisis screenings, identify patients in need of crisis stabilization services and appropriate for the Crisis

A) Please list the first Change Idea for the above Secondary Driver (required).

Utilize a crisis screening tool including medical exclusionary criteria to determine appropriateness for the Crisis Center.

B) Please list the second Change Idea for the above Secondary Driver (optional).

ii) Please describe the second Secondary Driver for the above Core Activity (optional).

B) Please list the second Change Idea for the above Secondary Driver (optional).

c) Please select the Measure Bundles or measures impacted by this Core Activity. If this core activity is not associated with any measure bundles or measures, please select "None" in the first dropdown.

M1-105	M1-147	M1-160	M1-210
M1-257	M1-264	M1-305	M1-317
M1-319			

i) Please describe how this Core Activity impacts the selected Measure Bundles or measures.

n the Crisis Center, individuals experiencing a mental health crisis are stabilized and assessed for additional edical concerns. These measures touch on important physical health components as well as managing ymptoms of mental illness. The Crisis Center provides a place for all of these things to be assessed, education provided to the indiviual and plans made for required follow up once discharged from the Crisis Center.

- d) Is this Core Activity provided by a provider that is not included in the Category B System Definition?
- 2) Please select the grouping for this Core Activity.

a) Please select the name of this Core Activity.

b) Please enter a description of this Core Activity

his core activity involves establishing a primary care clinic inside of a behavioral healthcare clinic Nurse Practitioner is utilized to diagnose acute and chronic disease conditions. Individuals are iagnosed, treated and medications provided. Health education including chronic disease nanagement through medications, nutrition and exercise is provided by a Chronic Care RN. This nic is located in the Behavioral Healthcare Clinic at Rosenberg but is open for others being served n behavioral healthcare services in the following clinics: Behavioral Healthcare Clinic at Wharton, ehavioral Healthcare Clinic at Bay City, Behavioral Healthcare Clinic at Brookshire, Behavioral Healthcare Clinic at Sugar Land. If these individuals are willing to drive or ride on our van to the osenberg Clinic, they can receive these primary care services. The clinic includes one Nurse ractitioner, one Chronic Care RN and one LVN.

i) Please describe the first Secondary Driver for the above Core Activity (required). mplement a medication adherence process for chronic conditions (i.e., uncontrolled hypertension or

- A) Please list the first Change Idea for the above Secondary Driver (required).
- B) Please list the second Change Idea for the above Secondary Driver (optional).
- ii) Please describe the second Secondary Driver for the above Core Activity (optional).
- c) Please select the Measure Bundles or measures impacted by this Core Activity. If this core activity is not associated with any measure bundles or measures, please select "None" in the first dropdown.

M1-105	M1-147	M1-210	M1-317
M1-211	M1-257	M1-203	M1-400
M1-182			

i) Please describe how this Core Activity impacts the selected Measure Bundles or measures.

individuals are identified in the behavioral healthcare clinic, they are referred to the Nurse Practitioner and Chronic Care RN for treatment and education including medications. For most individuals, they simply have not had the means to receive these services and pay for the medications. It is an opportunity for education egarding how substance abuse issues effect not only mental health but physical health as well. This core activity focuses on educating individuals the regarding tobacco and alcohol use and obsesity and the role these habits play in maintaining good physical health primarily with respect to uncontrolled hypertension and liabetes care. A large number of those we serve are at risk of Hepatitis C and this core activity focuses on testing and referral for follow up for this disease as well.

d) Is this Core Activity provided by a provider that is not included in the Category B System Definition?

DY7-8 Provider RHP Plan Update Template - Category D Progress Tracker Section 2: Verification Performing Provider Information 081522701 - Texana Center TPI and Performing Provider Name: Performing Provider Type: Community Mental Health Center (CMHC) Ownership: Non-State Owned Public If regional hospital participation Category D valuation in DY7 requirement is met Category D valuation in DY8 \$1,699,742.55 Category D valuation in DY7 If regional hospital participation \$566,580.85

Section 1: Statewide Reporting Measure Bundle for Community Mental Health Clinics (CMHCs)

Category D valuation in DY8

Measure	Category D valuation per DY distributed across measures (if regional hospital participation requirement is met)	Category D valuation per DY distributed across measures (if regional hospital participation requirement is not met)
Effective Crisis Response	\$339,948.51	\$113,316.17
Crisis Follow up	\$339,948.51	\$113,316.17
Community Tenure (Adult and Child/Youth)	\$339,948.51	\$113,316.17
Reduction in Juvenile Justice Involvement	\$339,948.51	\$113,316.17
Adult Jail Diversion	\$339,948.51	\$113,316.17

\$566,580.85

Section 2: Verification

requirement is not met

Please indicate below that you understand that Category D reporting requires qualitative reporting and data will be provided by HHSC as indicated in the Measure Bundle Protocol.

I understand

DY7-8 Provide	DY7-8 Provider RHP Plan Update Template - IGT Entry									
Progress	Tracker									
Section 1: IGT Entities Complete Section 1: IGT Entities Complete Section 2: IGT Funding Complete Section 3: Certification Complete										
Perform	ing Provider Information									
Performing Pr Ownership:	UP: 3 Pl and Performing Provider Name: 08152701 - Texansa Center Community Mental Health Center (CMHK.) Community Mental Health Center (CMHK.) Non-State Owned Public									
Section	1: IGT Entities									
In order to de	lete an existing IGT, delete the name of the IGT	from cell G21, G29, etc.				1				
IGT RHP	IGT Name		IGT TPI (if available)	le le	T TIN	Affiliation Number	1			
3	Texana Center		N/A	17602532875007		100-13-0000-00135				
	Contact Name	1	Street Address			Email	- 1		T	
Contact #	Amanda Darr	4910 Airport Avenue, Building D	Street Address	City	77471	amanda.darr@texanacenter.com	Phone Number 281-239-1350	Phone Extension	Lead Contact or Both	
2	Amanda Darr	4910 Airport Avenue, Building D		Rosenberg	77471	amanda.darr@texanacenter.com	281-239-1350		Both	
2										
_										
IGT RHP IGT Name IGT TPI (if available) IGT TIN Affiliation Number							7			
80.00										
Contact #	Contact Name		Street Address	City	Zip	Email	Phone Number	Phone Extension	Lead Contact or Both	
1	1								4	
2										
3									4	
	tester onto that a contact designated "Lead Contact" will be included in the RIPP Pan and on the DSRP IGT Distribution List. A contact designated as "Both" will be included in the RIPP Pan, on the DSRP IGT Distribution List, and will be given access to the DSRP Online monthly received.									

Section 2: IGT Funding

					If regional private hospital	participation requirement is	If regional private hospital participation requirement is		
	met				not	met			
							Total Estimated DY8	Total Estimated DY7	Total Estimated DY8
	IGT Name	IGT TIN	IGT Affiliation #	DY7 % IGT Allocated	DY8 % IGT Allocated	Allocation (FMAP 56.88/IGT	Allocation (FMAP 57.32/IGT	Allocation (FMAP 56.88/IGT	Allocation (FMAP 57.32/IGT
						43.12)	42.68)	43.12)	42.68)
RHP Plan Update Submission	Texana Center	17602532875007	100-13-0000-00135	100.00%		\$977.238.65		\$977.238.65	
Category B	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$488.619.33	\$483.633.41	\$488.619.33	\$483.633.41
M1-105	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$193,493.25	\$261,162.04	\$228,673.85	\$295,983.65
M1-147	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$206,930.28	\$279,298.30	\$244,553.97	\$316,538.07
M1-160	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$258,528,49	\$348,941,51	\$305,533,66	\$395,467,04
M1-182	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$206.930.28	\$279.298.30	\$244.553.97	\$316.538.07
M1-203	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$193,493.25	\$261,162.04	\$228,673.85	\$295,983.65
M1-210	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$206,930.28	\$279,298.30	\$244,553.97	\$316,538.07
M1-211	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$206,930,28	\$279,298,30	\$244,553,97	\$316.538.07
M1-257	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$206.930.28	\$279.298.30	\$244.553.97	\$316.538.07
M1-264	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$206,930.28	\$279,298.30	\$244,553.97	\$316,538.07
M1-305	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$206,930.28	\$279,298.30	\$244,553.97	\$316,538.07
M1-317	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$193,493,25	\$261.162.04	\$228.673.85	\$295,983,65
M1-319	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$206.930.28	\$279.298.30	\$244.553.97	\$316.538.07
M1-400	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$192,955.77	\$260,436.60	\$228,038.64	\$295,161.48
Category D	Texana Center	17602532875007	100-13-0000-00135	100.00%	100.00%	\$732,928.99	\$725,450.12	\$244,309.66	\$241,816.71
Total		_				\$4,886,193.25	\$4,836,334.14	\$4,886,193.25	\$4,836,334.14

Your funding allocations sum to 100%.

Have the IGT Entities and funding percentages been updated?

Yes

Section 3: Certification

By my signature below, I certify the following facts:

• I am legally authorized to sign this document on behalf of my organization;

• I have read and understand this document.

• I have read and understand this document.

• Armanda Duer

• Corporation:

• Tessand Duer

• Tessand Corporation:

Progress Tracker

Section 1: DY7-8 DSRIP Valuation

Section 1: DY7-8 DSRIP Valuation
Section 2: Category B Medicaid Low-income Uninsured (MLIU) Patient Population by Provider (PPP)
Section 3: Category C Measure Bundles/Measures Selection and Valuation
Section 4: Category A Core Activities Associated with Category C Measure Bundles/Measures
Section 5: Category D Valuations
Section 6: Certification

Performing Provider Information

TPI and Performing Provider Name: Performing Provider Type: Ownership:

Section 1: DY7-8 DSRIP Valuation									
		DY7-8 DSRIP Valuation Distribution							
	Valuation if regional private hospital hospital private hospital hospital private hospital hospital private hospital hospital private hospital hospital private hospital private hospital private hospital private hospital hospital private hospital hospit	participation requirement	Valuation if regional private hospital participation requirement is <u>not</u> met						
	DY7	DY8	DY7	DY8					
RHP Plan Update Submission	\$2,266,323.40	\$0.00	\$2,266,323.40	\$0.00					
Category A	\$0.00	\$0.00	\$0.00	\$0.00					
Category B	\$1,133,161.70	\$1,133,161.70	\$1,133,161.70	\$1,133,161.70					
Category C	\$6,232,389.35	\$8,498,712.75	\$7,365,551.05	\$9,631,874.45					
Category D	\$1,699,742.55	\$1,699,742.55	\$566,580.85	\$566,580.85					
Total	\$11,331,617.00	\$11,331,617.00	\$11,331,617.00	\$11,331,617.00					

Do you confirm the information in this section and acknowledge the understanding of limited allowed changes as described in the Program Funding and Mechanics Protocol and Measure Bundle Protocol?

Section 2: Category B Medicaid Low-income Uninsured (MLIU) Patient Population by Provider (PPP)

	MLIU PPP	Total PPP	MLIU Percentage of Total PPP
DY5	6,871	10,252	67.02%
DY6	6,765	10,194	66.36%
DY7 Estimated	6,818	10,223	66.69%
DY8 Estimated	6,818	10,223	66.69%

Were DY7-8 maintenance goals based on DY5 or DY6 only?

Do you confirm the information in this section and acknowledge the understanding of limited allowed changes as described in the Program Funding and Mechanics Protocol and Measure Bundle Protocol?

Yes

Section 3: Category C Measure Bundles/Measures Selection and Valuation

						Valuation if region participation rec		Valuation if region participation requi	
Bundle-Measure ID	Measure Bundle/Measure Name	# of Measures with Requested Achievement of Alternative Denominators	# of Measures with Requested Shorter or Delayed Measurement Periods	# of Measures with Requested Reporting Milestone Exemptions	Points	DY7 Valuation	DY8 Valuation	DY7 Valuation	DY8 Valuation
M1-105	Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention	0	1	0	2	\$448,732.03	\$611,907.32	\$530,319.68	\$693,494.96
M1-147	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	0	1	0	1	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33
M1-160	Follow-Up After Hospitalization for Mental Illness	0	0	0	3	\$599,555.86	\$817,576.17	\$708,566.01	\$926,586.32
M1-182	Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD-AD)	0	1	0	2	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33
M1-203	Hepatitis C: One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk	0	1	0	2	\$448,732.03	\$611,907.32	\$530,319.68	\$693,494.96
M1-210	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	0	1	0	1	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33
M1-211	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents	0	1	0	2	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33
M1-257	Care Planning for Dual Diagnosis	0	1	0	1	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33

M1-264	Vocational Rehabilitation for Schizophrenia	0	1	0	1	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33
M1-305	Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment (SRA-CH)	0	1	0	2	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33
M1-317	Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling	0	1	0	2	\$448,732.03	\$611,907.32	\$530,319.68	\$693,494.96
M1-319	Adult Major Depressive Disorder (MDD): Suicide Risk Assessment (eMeasure)	0	1	0	2	\$479,893.98	\$654,400.88	\$567,147.43	\$741,654.33
M1-400	Tobacco Use and Help with Quitting Among Adolescents	0	1	0	2	\$447,485.56	\$610,207.58	\$528,846.56	\$691,568.61
Total	N/A	0	12	0	23	\$6,232,389.35	\$8,498,712.75	\$7,365,551.05	\$9,631,874.45

Do you confirm the information in this section and acknowledge the understanding of limited allowed changes as described in the Program Funding and Mechanics Protocol and Measure Bundle Protocol?

Yes

Section 4: Category A Core Activities Associated with Category C Measure Bundles/Measure

Bundle-Measure ID	Measure Bundle/Measure Name	Associated Core Activities
M1-105	Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention	
M1-147	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	
M1-160	Follow-Up After Hospitalization for Mental Illness	
M1-182	Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD-AD)	
M1-203	Hepatitis C: One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk	
M1-210	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	
M1-211	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents	
M1-257	Care Planning for Dual Diagnosis	
M1-264	Vocational Rehabilitation for Schizophrenia	
M1-305	Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment (SRA-CH)	
M1-317	Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling	
M1-319	Adult Major Depressive Disorder (MDD): Suicide Risk Assessment (eMeasure)	
M1-400	Tobacco Use and Help with Quitting Among Adolescents	
M1-257	Care Planning for Dual Diagnosis	
M1-264	Vocational Rehabilitation for Schizophrenia	
M1-305	Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment (SRA-CH)	
M1-317	Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling	
M1-319	Adult Major Depressive Disorder (MDD): Suicide Risk Assessment (eMeasure)	
M1-400	Tobacco Use and Help with Quitting Among Adolescents	

Do you confirm the information in this section and acknowledge the understanding of limited allowed changes as described in the Program Funding and Mechanics Protocol and Measure Bundle Protocol?

Ye

Section 5: Category D Valuations

Statewide Reporting for CMHCs

Measure	Category D valuation per DY distributed across measures (if regional hospital participation requirement is met)	Category D valuation per DY distributed across measures (if regional hospital participation requirement is <u>not</u> met)
Effective Crisis Response	\$339,948.51	\$113,316.17
Crisis Follow up	\$339,948.51	\$113,316.17
Community Tenure (Adult and Child/Youth)	\$339,948.51	\$113,316.17
Reduction in Juvenile Justice Involvement	\$339,948.51	\$113,316.17
Adult Jail Diversion	\$339,948,51	\$113.316.17

Do you confirm the information in this section and acknowledge the understanding of limited allowed changes as described in the Program Funding and Mechanics Protocol and Measure Bundle Protocol?

Yes

Section 6: Certification

- By my signature below, I certify the following facts:

 I am legally authorized to sign this document on behalf of my organization;

 I have read and understand this document:

 The statements on this form regarding my organization are true, correct, and complete to the best of my knowledge and belief.

Name: Performing Provider: Date:

PROVIDER RHP PLAN UPDATE TEMPLATE PROGRESS: Template is COMPLETE!

Please confirm that the Provider RHP Plan Update template progress shows complete above. If it shows that the template is not ready for submission, please complete any missing steps and correct any outstanding issues before submitting to HHS.

Dunyiday Fatur	
Provider Entry	
Section 1: Performing Provider Information	Complete
Section 2: Lead Contact Information	Complete
Section 3: Optional Withdrawal From DSRIP	Complete
Section 4: Performing Provider Overview	Complete
Section 5: DY7-8 DSRIP Total Valuation	Complete
Category B	
Category B	
Section 1: System Definition	Complete
Section 2: Medicaid Low-income Uninsured (MLIU) Patient Population by Provider (PPP)	Complete
Category C Selection	
Section 1: Selection Overview (CMHCs and LHDs only)	Complete
Section 3: Selection of Measures for Community Mental Health Centers	Complete
Minimum Selection Requirements Met	Yes
MPT Met	Yes
Category C Additional Details	
Section 1: Measure Exemption Requests and Measure Setting System Components	Complete
Category C Valuation	
category e valuation	
Section 1: Measure Bundle/Measure Valuation	Complete
Category A Core Activities	
Section 1: Transition from DY2-6 Projects to DY7-8 Provider-Level Outcomes and Core Activities	Complete
Section 2: Core Activities	Complete
All Selected Measure Bundles/Measures Associated with at Least One Core Activity	Complete
7 in Selected incusarie Buildies/ incusaries 7 is soluted with at 2005 one objet/letivity	complete
Category D	
Section 1: Statewide Reporting Measure Bundle for Community Mental Health Clinics (CMHCs)	Complete
Section 2: Verification	Complete
Section 2. Verification	
IGT Entry	
	Complete
IGT Entry	Complete Complete
IGT Entry Section 1: IGT Entities	Complete Complete Complete
IGT Entry Section 1: IGT Entities Section 2: IGT Funding Section 3: Certification	Complete
IGT Entry Section 1: IGT Entities Section 2: IGT Funding	Complete
IGT Entry Section 1: IGT Entities Section 2: IGT Funding Section 3: Certification Summary and Certification	Complete Complete
IGT Entry Section 1: IGT Entities Section 2: IGT Funding Section 3: Certification Summary and Certification Section 1: DY7-8 DSRIP Valuation	Complete Complete Complete
IGT Entry Section 1: IGT Entities Section 2: IGT Funding Section 3: Certification Summary and Certification Section 1: DY7-8 DSRIP Valuation Section 2: Category B Medicaid Low-income Uninsured (MLIU) Patient Population by Provider (PPP)	Complete Complete Complete Complete
Section 1: IGT Entities Section 2: IGT Funding Section 3: Certification Summary and Certification Section 1: DY7-8 DSRIP Valuation Section 2: Category B Medicaid Low-income Uninsured (MLIU) Patient Population by Provider (PPP) Section 3: Category C Measure Bundles/Measures Selection and Valuation	Complete Complete Complete Complete Complete Complete
Section 1: IGT Entities Section 2: IGT Funding Section 3: Certification Summary and Certification Section 1: DY7-8 DSRIP Valuation Section 2: Category B Medicaid Low-income Uninsured (MLIU) Patient Population by Provider (PPP) Section 3: Category C Measure Bundles/Measures Selection and Valuation Section 4: Category A Core Activities Associated with Category C Measure Bundles/Measures	Complete Complete Complete Complete Complete Complete Complete
Section 1: IGT Entities Section 2: IGT Funding Section 3: Certification Summary and Certification Section 1: DY7-8 DSRIP Valuation Section 2: Category B Medicaid Low-income Uninsured (MLIU) Patient Population by Provider (PPP) Section 3: Category C Measure Bundles/Measures Selection and Valuation	Complete Complete Complete Complete Complete Complete